Terms: = Endocrine gland cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
46 results:
1. Identification and validation of an anoikis-related genes signature for prognostic implication in papillary thyroid cancer.
Zhao R; Lu Y; Wan Z; Qiao P; Yang L; Zhang Y; Huang S; Chen X
Aging (Albany NY); 2024 Apr; 16(8):7405-7425. PubMed ID: 38663918
[TBL] [Abstract] [Full Text] [Related]
2. ezh2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
3. A clinically useful and biologically informative genomic classifier for papillary thyroid cancer.
Craig S; Stretch C; Farshidfar F; Sheka D; Alabi N; Siddiqui A; Kopciuk K; Park YJ; Khalil M; Khan F; Harvey A; Bathe OF
Front Endocrinol (Lausanne); 2023; 14():1220617. PubMed ID: 37772080
[TBL] [Abstract] [Full Text] [Related]
4. ezh2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacological inhibition of ezh2 using a covalent inhibitor suppresses human ovarian cancer cell migration and invasion.
Shi L; Zhang Q; Zhu S; Tang Q; Chen X; Lan R; Wang N; Zhu Y
Mol Cell Biochem; 2024 Apr; 479(4):831-841. PubMed ID: 37199893
[TBL] [Abstract] [Full Text] [Related]
6. Validation of ezh2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract] [Full Text] [Related]
7. The epigenetic factor CHD4 contributes to metastasis by regulating the ezh2/β-catenin axis and acts as a therapeutic target in ovarian cancer.
Wang J; Zhong F; Li J; Yue H; Li W; Lu X
J Transl Med; 2023 Jan; 21(1):38. PubMed ID: 36681835
[TBL] [Abstract] [Full Text] [Related]
8. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine.
Wang ZW; Pan JJ; Hu JF; Zhang JQ; Huang L; Huang Y; Liao CY; Yang C; Chen ZW; Wang YD; Shen BY; Tian YF; Chen S
Cell Rep; 2022 May; 39(6):110813. PubMed ID: 35545048
[TBL] [Abstract] [Full Text] [Related]
9. SOX8 Affects Tumoral SPARC Expression by Regulating ezh2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.
Yuan S; Xu J; Zhou B; Zhou Y; Lang M; Cao J; Liu Z; Yang S; Gao S; Hao J
Int J Biol Sci; 2022; 18(3):911-922. PubMed ID: 35173526
[TBL] [Abstract] [Full Text] [Related]
10. Dual G9A/ezh2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
11. Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/ezh2 complex in pancreatic cancer.
Sun Y; Ren D; Zhou Y; Shen J; Wu H; Jin X
Cell Death Dis; 2021 Sep; 12(10):878. PubMed ID: 34564701
[TBL] [Abstract] [Full Text] [Related]
12. ezh2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
13. Long noncoding RNA ATB promotes ovarian cancer tumorigenesis by mediating histone H3 lysine 27 trimethylation through binding to ezh2.
Chen XJ; An N
J Cell Mol Med; 2021 Jan; 25(1):37-46. PubMed ID: 33336896
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression.
Chen S; Huang L; Li G; Qiu F; Wang Y; Yang C; Pan J; Wu Z; Chen J; Tian Y
Clin Epigenetics; 2020 Nov; 12(1):168. PubMed ID: 33160411
[TBL] [Abstract] [Full Text] [Related]
15. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1.
Zhai S; Xu Z; Xie J; Zhang J; Wang X; Peng C; Li H; Chen H; Shen B; Deng X
Oncogene; 2021 Jan; 40(2):277-291. PubMed ID: 33122827
[TBL] [Abstract] [Full Text] [Related]
16. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract] [Full Text] [Related]
17. Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated ezh2 and SIRT1.
Zhang Y; Ai H; Fan X; Chen S; Wang Y; Liu L
Biol Res; 2020 Apr; 53(1):18. PubMed ID: 32349783
[TBL] [Abstract] [Full Text] [Related]
18. ezh2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic cancer Cell Proliferation
Agrawal R; Chen M; Bukhari Z; Ogunwobi OO; Haseeb MA; Martello LA
Ann Clin Lab Sci; 2020 Jan; 50(1):45-56. PubMed ID: 32161011
[TBL] [Abstract] [Full Text] [Related]
19. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract] [Full Text] [Related]
20. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating ezh2 in pancreatic ductal adenocarcinoma (PDAC).
Xie F; Huang Q; Wang C; Chen S; Liu C; Lin X; Lv X; Wang C
Cancer Biomark; 2020; 27(3):357-364. PubMed ID: 31929143
[TBL] [Abstract] [Full Text] [Related]
[Next]
